Get a free sample of Aniridia Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Aniridia Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Aniridia Treatment Market Size
Aniridia Treatment Market size was valued at around USD 2.6 billion in 2023 and is estimated to grow at 5.1% CAGR from 2024 to 2032. The market has experienced significant growth due to the increasing prevalence of aniridia.
According to the American Academy of Ophthalmology, the occurrence of aniridia is estimated at around 1.8 per 100,000 live births, with an incidence varying between 1 in 40,000 to 1 in 100,000. Thus, as the awareness and diagnosis of rare diseases are increasing, there is a corresponding rise in demand for effective rare disease treatment options, stimulating research, development (R&D), and investment in therapies tailored to managing this rare genetic disorder.
Aniridia treatment refers to medical interventions aimed at managing and alleviating the symptoms associated with aniridia, a rare genetic disorder characterized by the partial or complete absence of the iris in the eye. Treatment approaches may include supportive medication and surgical procedures to improve vision and manage complications such as glaucoma, cataracts, and other eye disease conditions.
Which prominent players are operating in the aniridia treatment market?
Key players operating in the aniridia treatment market are AbbVie Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd, HumanOptics AG, Johnson & Johnson Vision, MORCHER GmbH, Novartis AG, Ophtec, Pfizer Inc., and REPER-NN LTD are among others.
How substantial is the aniridia treatment market in North America?
North America aniridia treatment industry will grow at a significant CAGR up to 2032, driven by advanced healthcare infrastructure, a high prevalence of genetic disorders, and significant investments in research and development.
Why is the demand for congenital aniridia treatment rising?
The congenital aniridia segment recorded 88.5% of the market share in 2023, attributed to higher prevalence compared to acquired forms.
What is the size of the aniridia treatment market?
Aniridia treatment industry size registered USD 2.6 billion in 2023 and will demonstrate a 5.1% CAGR from 2024 to 2032, owing to rising prevalence of aniridia, advancements in genetic testing, increasing healthcare expenditure, and favorable regulatory initiatives.